
The Anti-Biofilm Mechanism of Bactorinol®: The Core of Its Clinical Innovation
After presenting the clinical efficacy of Bactorinol® in our previous article “Bactorinol® Nasal Drops: A Study Confirms Its Potential Against Chronic RhinoSinusitis”, a new study published in Minerva Medica finally clarifies how Winterized Lentisk Oil (WLO) achieves these results. Recent in-vitro evidence demonstrates that Bactorinol® not only prevents bacterial biofilm formation but can also break down existing biofilm — a breakthrough in understanding CRS recurrence. This dual action, combined with the ongoing successful MDR regulatory pathway, reinforces Bactorinol® as a high-value medical device with strong strategic potential.














































